CEO Martin Vidaeus explains about development through toxicology and safety studies.
RP101 is the company’s main development program of a new treatment of chronic dry eye disease in postmenopausal women. The active substance is a molecule that has already shown safety and efficacy in two clinical phase II studies conducted in the United States. The active substance has now been formulated in IntelliGel® to control release, reduce the number of doses and increase comfort. Redwood Pharma will conduct a Phase II clinical trial of RP101 in Europe. Chronic dry eye disease represents a large market with high medical needs. The market is expected to grow to $2.7 billion in 2022. RP101 will be the first treatment to restore a biological mechanism to treat a patient group of women after menopause. As there are already data from both development and clinics, the project is estimated to be able to come to the market more quickly, as well as lower capital requirements and development risks than programs based on new chemical substances.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com